Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magali Joffraud

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Diabetes|September 11, 2016
Mfn1 Deficiency in the Liver Protects Against Diet-Induced Insulin Resistance and Enhances the Hypoglycemic Effect of MetforminSameer S Kulkarni, Magali Joffraud, Marie Boutant, et al.
Molecular Metabolism|November 27, 2019
A reduced form of nicotinamide riboside defines a new path for NAD<sup>+</sup> biosynthesis and acts as an orally bioavailable NAD<sup>+</sup> precursorJudith Giroud-Gerbetant, Magali Joffraud, Maria Pilar Giner, et al.
Nature Communications|October 12, 2016
NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cellsJoanna Ratajczak, Magali Joffraud, Samuel A J Trammell, et al.
Nature Communications|September 22, 2019
Endogenous nicotinamide riboside metabolism protects against diet-induced liver damageAudrey Sambeat, Joanna Ratajczak, Magali Joffraud, et al.
Cell Reports|August 25, 2021
Crosstalk between Drp1 phosphorylation sites during mitochondrial remodeling and their impact on metabolic adaptationMiriam Valera-Alberni, Magali Joffraud, Joan Miro-Blanch, et al.
Journal of Translational Medicine|January 9, 2013
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion proteinJulien Laurent, Cedric Touvrey, Silke Gillessen, et al.
Nature Communications|March 26, 2026
Therapeutic potential of dihydronicotinamide riboside (NRH) on obesity and glucose intolerance in miceMarie Rumpler, Guido van Mierlo, Kasper T Vinten, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Diabetes|September 11, 2016
Mfn1 Deficiency in the Liver Protects Against Diet-Induced Insulin Resistance and Enhances the Hypoglycemic Effect of MetforminSameer S Kulkarni, Magali Joffraud, Marie Boutant, et al.
Molecular Metabolism|November 27, 2019
A reduced form of nicotinamide riboside defines a new path for NAD<sup>+</sup> biosynthesis and acts as an orally bioavailable NAD<sup>+</sup> precursorJudith Giroud-Gerbetant, Magali Joffraud, Maria Pilar Giner, et al.
Nature Communications|October 12, 2016
NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cellsJoanna Ratajczak, Magali Joffraud, Samuel A J Trammell, et al.
Nature Communications|September 22, 2019
Endogenous nicotinamide riboside metabolism protects against diet-induced liver damageAudrey Sambeat, Joanna Ratajczak, Magali Joffraud, et al.
Cell Reports|August 25, 2021
Crosstalk between Drp1 phosphorylation sites during mitochondrial remodeling and their impact on metabolic adaptationMiriam Valera-Alberni, Magali Joffraud, Joan Miro-Blanch, et al.
Journal of Translational Medicine|January 9, 2013
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion proteinJulien Laurent, Cedric Touvrey, Silke Gillessen, et al.
Nature Communications|March 26, 2026
Therapeutic potential of dihydronicotinamide riboside (NRH) on obesity and glucose intolerance in miceMarie Rumpler, Guido van Mierlo, Kasper T Vinten, et al.
Pageof 2